Wockhardt Bio AG vs AstraZeneca AB

Replacement Decision Grant of Motion for Joinder

Decision - Grant Motion for Joinder

Patent Owner's Preliminary Response

Joint Stipulation Regarding Joinder

Revised Certificate of Service

PATENT OWNERS EXHIBIT LIST (as of June 27 2016)

AstraZeneca Exhibit 2005

Order - Conduct of the Proceedings - 37 CFR 42.5

Power of Attorney

Related Matters

PATENT OWNER'S OPPOSITION TO JOINDER

PATENT OWNER'S EXHIBIT LIST (as of May 31, 2016)

AstraZeneca Exhibit 2001

AstraZeneca Exhibit 2002

AstraZeneca Exhibit 2003

AstraZeneca Exhibit 2004

Notice Of Filing Date Accorded To Petition

Petitioner Wockhardt Bio Ag s Unopposed Motion for Pro Hac Vice Admission of Frederick R. Ball

WOCK Ex 1028 Declaration of Frederick R. Ball in Support of Petitioner Wockhardt Bio Ag s Unopposed Motion for Pro Hac Vice Admission

Petition For Inter Partes Review of U.S. Patent No. Re44,186

Power of Attorney

Motion for Joinder RE44186.pdf

WOCK Ex 1001 U.S. Reissue Patent 44,186 E to Robl et al. reissued Apr. 30, 2013

WOCK Ex 1002 U.S. Patent No. 6,395,767 to Robl et al. issued May 28, 2002

WOCK Ex 1003 Declaration of David P. Rotella, Ph.D.

WOCK Ex 1004 Curriculum Vitae of David P. Rotella, Ph.D.

WOCK Ex 1005 File History of U.S. Patent No. 6,395,767 to Robl et al. part 1

WOCK Ex 1005 File History of U.S. Patent No. 6,395,767 to Robl et al. part 2

WOCK Ex 1005 File History of U.S. Patent No. 6,395,767 to Robl et al. part 3

WOCK Ex 1006 File History of U.S. Reissued Patent 44,186 E to Robl et al. part 1

WOCK Ex 1006 File History of U.S. Reissued Patent 44,186 E to Robl et al. part 2

WOCK Ex 1007 Doreen M. Ashworth et al., 2-cyanopyrrolidides as potent, stable inhibitors of dipeptidyl peptidase IV, 6 BIOORG. and MED. CHEM. LTRS. 1163 1996

WOCK Ex 1008 WO Patent App. Pub. No. 9819998 to Villhauer pubd May 14,1998

WOCK Ex 1009 Reetta Raag and Thomas L. Poulos, Crystal Structure of Cytochrome P 450CAM Complexed with Camphane, Thiocamphor, and Adamantane Factors Controlling P 450 Substrate Hydroxylation, 30 BIOCHEMISTRY 2674 1991

WOCK Ex 1010 Stephen Hanessian et al., The Synthesis of Enantiopure ¿-Methanoprolines and ¿-Methanopipecolic Acids by a Novel Cyclopropanation Reaction The Flattening of Proline, 36 ANGEW. CHEM. ED. ENGL. 1881 1997

WOCK Ex 1011 WO Patent App. Pub. No. 9938501 to Bachovchin et al. pubd Aug. 5, 1999

WOCK Ex 1012 GLUCOPHAGE Label available by FOIA Jan. 8, 1998

WOCK Ex 1013 XENICAL Label available by FOIA Aug. 9, 1999

WOCK Ex 1014 MEVACOR Label available by FOIA Sept. 15, 1994

WOCK Ex 1015 Jian Lin et al., Inhibitin of dipeptidyl peptidase IV by fluoroolefin- containing N-peptidyl-O-hydroxylamine peptidomimetics, 95 PROC. NATL. ACAD. SCI. USA 14020 1998

WOCK Ex 1016 Howared E. Hoffman et al., Pharmacokinetics and Metabolism of Rimantadine Hydrochloride in Mice and Dogs, 32 11 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 1699 1988

WOCK Ex 1017 Christopher A. Lipinski et al., Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, 23 ADV. DRUG DELIV. REV. 3 1996

WOCK Ex 1018 Hansch et al., Cluster Analysis and the Design of Congener Sets, in SUBSTITUENT CONSTANTS FOR CORRELATION ANALYSIS IN CHEMISTRY AND BIOLOGY 48 John Wiley and Sons1979

WOCK Ex 1019 Lindley A. Cates, Calculation of Drug Solubilities by Pharmacy Students, 45 Am. J. Pharm. Educ. 11 1981

WOCK Ex 1020 Walter A. Korfmacher et al., HPLC API MS MS a powerful tool for integrating drug metabolism into the drug discovery process, 2 DRug Disc. Today 532 1997

WOCK Ex 1021 C. Y. Chiou et al., The Cholinergic Effects and Rates of Hydrolysis of Conformationally Rigid Analogs of Acetylcholine, 166 J. Pharm. Exp. Ther. 243 1969

WOCK Ex 1022 Daniel E. Koshland, Jr., The Key-Lock Theory and the Induced Fit Theory, 33 ANGEW. CHEM. ED. ENGL. 2375 1994

WOCK Ex 1023 E.J. Ariens and A. M. Simonis, Optimalization of Pharmacokinetics An Essential Aspect of Drug Development by Metabolic Stabilization, Pharmacochem. Lib., in 4 PHARMACOCHEM. LIB. 165 1982

WOCK Ex 1024 R Scott Obach Prediction of Human Clearance of Twenty nine Drugs from Hepatic Microsomal Intrinsic Clearance Data An Examination of In Vitro Half life Approach and Nonspecific Binding to Microsomes

WOCK Ex 1025 Yung chi Cheng and William H. Prusoff, Relationship Between the Inhibition Constant KI and the Concentration of Inhibitor which Causes 50 Per Cent Inhibition I50 of an Enzymatic Reaction

WOCK Ex 1026 Debnath Pal and Pinak Chakrabarti, Cis Peptide Bonds in Proteins Residues Involved, their Conformations, Interactions and Location, 294 J. of Mol. Biol. 271 1999

WOCK Ex 1027 US Provisional Patent Application No. 601888,555 to Robl